Abstract
Overview
Introduction
This analysis examines the historical and forecast performance for Eisai in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Key reasons to read this report
- Benchmark Eisai' s performance against key rivals in the ethical pharmaceutical sector
- See how Eisai will suffer negative growth out to 2012, driven by the decline of its two biggest products, the blockbusters Aricept and Aciphex
- Evaluate the company' s long-term growth prospects following the 2007 acquisition of US biotech Morphotek
View Cart
